Koch Disruptive, an investment firm, led a $255m Series C round in Cellares, an Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, with participation from Bristol Myers Squibb, DFJ Growth, Willett Advisors and Eclipse, Decheng Capital, and 8VC. "Cell therapies have tremendous curative potential across a wide range of diseases. But right now, manufacturing by conventional CDMOs is expensive, failure-prone, and impossible to scale. Cellares is driving transformation in the marketplace by combining an Industry 4.0 approach with full vertical integration. As the first IDMO, Cellares is empowering cell therapy companies to build viable businesses, remain competitive, and meet the needs of fast-growing patient populations," David Mauney, Koch Disruptive Technologies Managing Director.